New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

Hdl Handle:
http://hdl.handle.net/10144/619004
Title:
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations
Authors:
Harausz, E; Garcia-Prats, A; Seddon, J; Schaaf, H; Hesseling, A; Achar, J; Bernheimer, J; Cruz, A; D'Ambrosio, L; Detjen, A; Graham, S; Hughes, J; Jonckheere, S; Marais, B; Migliori, G; McKenna, L; Skrahina, A; Tadolini, M; Wilson, P; Furin, J
Journal:
American Journal of Respiratory and Critical Care Medicine
Abstract:
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
Publisher:
American Thoracic Society
Issue Date:
15-May-2017
URI:
http://hdl.handle.net/10144/619004
DOI:
10.1164/rccm.201606-1227CI
PubMed ID:
27854508
Submitted date:
2017-07-24
Language:
en
Description:
We regret that this article is behind a paywall.
ISSN:
1535-4970
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorHarausz, Een
dc.contributor.authorGarcia-Prats, Aen
dc.contributor.authorSeddon, Jen
dc.contributor.authorSchaaf, Hen
dc.contributor.authorHesseling, Aen
dc.contributor.authorAchar, Jen
dc.contributor.authorBernheimer, Jen
dc.contributor.authorCruz, Aen
dc.contributor.authorD'Ambrosio, Len
dc.contributor.authorDetjen, Aen
dc.contributor.authorGraham, Sen
dc.contributor.authorHughes, Jen
dc.contributor.authorJonckheere, Sen
dc.contributor.authorMarais, Ben
dc.contributor.authorMigliori, Gen
dc.contributor.authorMcKenna, Len
dc.contributor.authorSkrahina, Aen
dc.contributor.authorTadolini, Men
dc.contributor.authorWilson, Pen
dc.contributor.authorFurin, Jen
dc.date.accessioned2017-09-06T12:12:57Z-
dc.date.available2017-09-06T12:12:57Z-
dc.date.issued2017-05-15-
dc.date.submitted2017-07-24-
dc.identifier.citationNew and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. 2017, 195 (10):1300-1310 Am. J. Respir. Crit. Care Med.en
dc.identifier.issn1535-4970-
dc.identifier.pmid27854508-
dc.identifier.doi10.1164/rccm.201606-1227CI-
dc.identifier.urihttp://hdl.handle.net/10144/619004-
dc.descriptionWe regret that this article is behind a paywall.en
dc.description.abstractIt is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.en
dc.language.isoenen
dc.publisherAmerican Thoracic Societyen
dc.subject.meshAdolescenten
dc.subject.meshAntitubercular Agentsen
dc.subject.meshChilden
dc.subject.meshHumansen
dc.subject.meshPractice Guidelines as Topicen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.titleNew and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendationsen
dc.identifier.journalAmerican Journal of Respiratory and Critical Care Medicineen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.